Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

Centre hospitalier de l'Université de Montréal (CHUM)

$1,093,950.00

Targeting the novel cell adhesion molecule DICAM to curb myeloid cell-associated neuroinflammation

EF 2025-26

Résumé
Immune cells are important for staying healthy, as they patrol our body to find and destroy microbes. However, these immune cells can malfunction and cause more harm than good. Normally, the blood-brain barrier (BBB) protects the brain from such infiltration by controlling the passage of immune cells. In inflammatory diseases such as Multiple Sclerosis (MS), aggressive immune cells from the blood travel to the brain where they cause tissue damage. These include immune cells such as lymphocytes, monocytes and dendritic cells. The movement of such aggressive immune cells from the blood to the brain is orchestrated by many factors, including cell adhesion molecules (CAMs). Blocking these CAMs decreases the symptom of MS, but can leave the brain vulnerable to microbes. We have identified DICAM as a novel CAM molecule found on monocytes, macrophages, and dendritic cells. It seems to play a central role in the migration of specifically bad immune cells into the brain, and would allow good immune cells to patrol the brain. The goal of my current project is to show how DICAM causes infiltration of immune cells into the brain, describe the cells that express DICAM, and to see if targeting this molecule could improve MS treatment with fewer side effects. This project has the potential to pave the way for more selective therapeutic agents against MS, improving the quality of life of people with MS.
Programme
Project Grant
Emplacement
Quebec, Canada
Type de bénéficiaire
Not-for-profit organization or charity
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
532008
Name
Prat Alexandre
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Molecular & Cellular Neurosciences - B
Projecttitle
Targeting the novel cell adhesion molecule DICAM to curb myeloid cell-associated neuroinflammation
Programtype2
Operating Grants
Orgnameinp2
Centre hospitalier de l'Université de Montréal (CHUM)
Cihramount2
$1,093,950
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Blood-Brain Barrier; Cellular Adhesion Molecules; Cns Infiltration; Dicam; Endothelial Cells; Experimental Autoimmune Encephalomyelitis; Multiple Sclerosis; Myeloid Cells; Neuroimmunology; Sincle-Cell Transcriptomics
Abstract
Immune cells are important for staying healthy, as they patrol our body to find and destroy microbes. However, these immune cells can malfunction and cause more harm than good. Normally, the blood-brain barrier (BBB) protects the brain from such infiltration by controlling the passage of immune cells. In inflammatory diseases such as Multiple Sclerosis (MS), aggressive immune cells from the blood travel to the brain where they cause tissue damage. These include immune cells such as lymphocytes, monocytes and dendritic cells. The movement of such aggressive immune cells from the blood to the brain is orchestrated by many factors, including cell adhesion molecules (CAMs). Blocking these CAMs decreases the symptom of MS, but can leave the brain vulnerable to microbes. We have identified DICAM as a novel CAM molecule found on monocytes, macrophages, and dendritic cells. It seems to play a central role in the migration of specifically bad immune cells into the brain, and would allow good immune cells to patrol the brain. The goal of my current project is to show how DICAM causes infiltration of immune cells into the brain, describe the cells that express DICAM, and to see if targeting this molecule could improve MS treatment with fewer side effects. This project has the potential to pave the way for more selective therapeutic agents against MS, improving the quality of life of people with MS.
Competitiondate
202509
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Prat, Alexandre
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,093,950~ $0~